以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 肥胖已经成为威胁全球健康的重要公共卫生难题。目前，全球大约有40%的成年人处于超重或肥胖状态。根据《中国居民营养与慢性病状况报 告（2020年）》的数据，我国成年人口中超重或肥胖的比例已超过一半，学龄儿童中接近五分之一存在体重超标。肥胖会显著增加多种慢性疾 病和过早死亡的风险，给家庭和社会带来沉重的健康和经济压力。 2018年，王存川教授联合中国医师协会外科医师分会肥胖和糖尿病外科医师委员会全体成员，倡议将每年5月11日设为"中国肥胖 日"。"5.11"寓意"我要腰、我要瘦"，倡导大家关注肥胖问题，积极参与预防和控制。 那么，如何才能科学又健康地减重？《中国居民健康体重管理之减重行动20条：基于科学循证的专家建议共识》从饮食、运动、行为干预三个 方面，提出了切实可行的减重建议。 ▍减重，怎么吃？ 《共识》提出，在控制总热量的前提下，坚持以谷物为主的均衡饮食，有助于健康减重。每天的饮食应涵盖谷薯类、蔬果、畜禽鱼蛋奶及豆制 品，并减少油脂、盐分和糖分的摄入 ...

针对特朗普的关税大棒，诺和诺德近日强烈呼吁美国商务部不要对药品征收关税，警告此类举措可能会扰乱关键药物的获取渠道。 这家丹麦制药公司在5月6日致该部门的一封信中阐述了其立场，此信是对商务部就"232条款"关于药品进口是否构成国家安全风险所发起征求意 见的正式回应。诺和诺德并不支持对所有药品进口一刀切地征收关税，而是建议商务部重点调查来源不明的司美格鲁肽进口——该成分是其畅销 药物Wegovy和Ozempic的有效成分——以评估这些非法进口是否构成国家安全威胁。 诺和诺德特别指出来自中国的"未经授权的司美格鲁肽"，并称这些进口妨碍了其在美国的投资，并可能威胁国家安全。该公司表示，美国食品药 品监督管理局（FDA）对这些中国仿制司美格鲁肽的制造商缺乏有效监管，而这些产品正在通过配制药的方式流入美国市场，直接提供给患者。 此外，诺和诺德还指出中国监管体系自身也存在监管不足的问题。在已知的19家向美国出口司美格鲁肽原料的中国企业中，有12家"被认为不符 合司美格鲁肽生产的良好生产规范（GMP）要求"。 诺和诺德呼吁商务部将重点放在打击此类非法进口产品上，并与"欧洲盟友"共同建立更加稳固的药品供应链。公司在信中表示，虽 ...

整理 | GLP1减重宝典内容团队 替尔泊肽是一款葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体的双重激动剂，它通过模拟GLP-1和GIP的作用来 降低血糖水平。GLP-1和GIP是一种肠道激素，它在血糖升高时促进胰岛素的分泌，并在血糖正常时抑制胰高血糖素的分泌，从而有助于维持血 糖平衡。替尔泊肽的降糖作用是葡萄糖依赖性的，这意味着 它只在血糖水平升高时才会促进胰岛素的释放 ，而在血糖水平正常或降低时，其促 进胰岛素分泌的作用会减弱或停止。 因此，对于血糖正常的健康人来说，替尔泊肽不会引起低血糖，因为 它不会在血糖正常时刺激胰岛素的过量分泌 。这一特性使得替尔泊肽在治 疗2型糖尿病和肥胖患者时相对安全，因为它可以帮助控制餐后血糖升高而不会导致低血糖风险。 ▍ 替尔泊肽降糖的作用机制 尽管目前有多种降糖药物可供选择，但许多患者仍难以达到理想的血糖控制目标。传统的降糖药物如二甲双胍、磺脲类和胰岛素虽然有效，但 在体重增加、低血糖风险等方面存在局限性。因此，开发新型降糖药物成为医学界关注的焦点。近年来，胰高血糖素样肽-1（GLP-1）受体激 动剂因其多重代谢获益而备受关注。替尔泊肽和司 ...

Core Viewpoint - The article highlights the alarming rise in obesity rates among Chinese adults, with over 400 million classified as overweight or obese, prompting national health initiatives to address this public health crisis [4][7][19]. Group 1: Current Obesity Situation - As of 2021, China has 402 million adults aged 25 and above who are overweight or obese, ranking first globally [7]. - Projections indicate that by 2025, 41% of adults will have a BMI of 25 or higher, and by 2030, the number of overweight or obese adults could reach 515 million [7][19]. - The obesity trend shows a clear north-south divide, with northern provinces exhibiting higher obesity rates compared to southern regions [8][10]. Group 2: Health Implications - Obesity is linked to over 200 diseases, including hypertension, diabetes, and heart disease, with 2.8 million deaths globally attributed to obesity each year [4][14]. - The economic burden of obesity-related healthcare costs in China is projected to exceed 400 billion yuan by 2025 [4][19]. Group 3: National Response - The Chinese government has initiated a three-year "Weight Management Year" action plan, targeting various demographics for scientific weight management interventions [19][21]. - A national-level weight loss diet plan has gained popularity, promoting a balanced diet while considering regional culinary preferences [18][19]. - Hospitals across China are establishing weight management clinics, with 245 tertiary hospitals already offering such services [21][22]. Group 4: Lifestyle Factors - The rise in obesity is attributed to urbanization, leading to decreased physical activity and changes in dietary habits, with a significant increase in the consumption of ultra-processed foods [31][24]. - Data shows that from 2012 to 2016, the consumption of ultra-processed foods in China increased 2 to 3 times, with average annual consumption rising significantly [24]. - The average weekly exercise time for the population is only 1.1 hours, contributing to energy imbalance and weight gain [33][34].

整理 | GLP1减重宝典内容团队 替尔泊肽是一种新型的每周一次的 GIP（葡萄糖依赖性胰岛素促泌多肽）受体和 GLP-1（胰高血糖素样肽-1）受体激动剂，代表了一类正在研 究的治疗肥胖症的药物。替尔泊肽是一种激活人体 GIP 和 GLP-1 受体（两种天然肠促胰岛素激素）的单肽。 肥胖症是一种慢性进行性疾病，由控制体重的机制中断引起，通常导致食物摄入量增加和/或能量消耗减少。这些中断是多因素的，可能与遗 传、发育、行为、环境和社会因素有关。 ▍个体差异显著：替尔泊肽并非人人适用 在SURMOUNT-1试验中，研究招募了 2,539 名参与者，参与者的平均基线体重为105 公斤。 试验结果平均体重减轻：16.0%（5 毫克时16 公斤）、21.4%（10 毫克时22 公斤）和 22.5%（15 毫克时24 公斤），而安慰剂组（2.4%或 2 公 斤）。 然而要达到这样的效果，试验引入了低热量饮食和增加身体活动的辅助手段 ，所以要达到这样的效果需搭配生活方式改变。 89%（5 毫克）和 96%（10 毫克和 15 毫克）的人体重减轻了至少 5%，而服用安慰剂的人中，这一比例仅为 28%。 所以替尔泊肽对有的人可 ...

Core Viewpoint - Guangzhou Yinnuo Pharmaceutical Group Co., Ltd. has received a notice for the registration of its overseas issuance and listing, indicating a significant step towards its planned public offering in Hong Kong [1][3]. Group 1 - The company plans to issue up to 69,043,500 overseas listed ordinary shares and list them on the Hong Kong Stock Exchange [3]. - A total of 45 shareholders intend to convert their combined 383,729,000 unlisted shares into overseas listed shares for trading on the Hong Kong Stock Exchange [5]. - The company is required to report any major events to the China Securities Regulatory Commission (CSRC) from the date of the notice until the completion of the overseas issuance and listing [5][6]. Group 2 - The company must update its registration materials if it does not complete the overseas issuance and share conversion within 12 months from the date of the notice [6]. - The notice confirms the registration of the company's overseas issuance and "full circulation" of shares but does not imply any judgment or guarantee regarding the investment value or returns for investors [6].

Core Viewpoint - GLP-1 receptor agonists, such as semaglutide, have shown significant efficacy in treating type 2 diabetes and obesity, but they are often associated with gastrointestinal side effects that can affect patient adherence to treatment. Supplementing with probiotics, particularly bifidobacteria, may help alleviate these side effects and improve patient experience [2][3][14]. Group 1: Semaglutide's Effects and Side Effects - Semaglutide is a GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1, promoting insulin secretion, inhibiting gastric emptying, and reducing appetite, leading to blood sugar reduction and weight loss [3]. - Approximately 40% to 70% of patients experience gastrointestinal discomfort, such as nausea, vomiting, diarrhea, and constipation, during treatment, which may be linked to the drug's mechanisms of delaying gastric emptying and affecting intestinal motility [3]. Group 2: Probiotic Benefits - Bifidobacteria are common probiotics found in the human gut, especially dominant in infancy, and they help maintain gut health by regulating gut microbiota, inhibiting harmful bacteria growth, enhancing gut barrier function, modulating immune responses, and promoting nutrient absorption [5][6][7][8]. Group 3: Mechanisms of Probiotics in Alleviating GLP-1 Drug Side Effects - Supplementing with bifidobacteria may alleviate gastrointestinal side effects caused by GLP-1 drugs by restoring gut microbiota balance disrupted by these medications, thereby reducing gastrointestinal symptoms [9]. - Probiotics enhance gut barrier function, promoting mucosal repair and reducing intestinal permeability, which prevents inflammatory factors from entering the bloodstream [10]. - They can also regulate gastrointestinal motility by influencing the enteric nervous system, alleviating symptoms like constipation or diarrhea [11]. - Probiotics produce beneficial metabolites, such as short-chain fatty acids, which help regulate gut pH and inhibit harmful bacteria growth, improving gut environment [12]. Group 4: Clinical Research and Application Prospects - Multiple studies indicate that supplementing with bifidobacteria can help alleviate gastrointestinal side effects from GLP-1 drugs, thereby improving patient adherence to treatment. For instance, Lactobacillus bifidum MN-Gup has shown positive effects in treating type 2 diabetes by improving gut microbiota, enhancing gut barrier function, and modulating immune responses [14]. - Probiotics may also lower inflammation by modulating the TLR4/MyD88/NF-κB signaling pathway, which could benefit patients with gastrointestinal disorders like irritable bowel syndrome [15]. - For patients experiencing gastrointestinal discomfort while using semaglutide or other GLP-1 drugs, considering the addition of bifidobacteria probiotics under medical guidance may help alleviate adverse reactions and enhance treatment experience. Overall, the supplementation of bifidobacteria presents a promising method for mitigating gastrointestinal side effects from GLP-1 drugs, warranting further clinical application [15].

越来越多人开始使用司美格鲁肽减肥，但是使用时，仍有很多疑问。现在我们就来解答关于 口服 司美格鲁肽片的10大常见问题，帮助你更安 全、更有效地达到减重目标。 ▍ 能减多少斤？ 目前全球范围内口服剂型的司美格鲁肽尚未获批用于减重，国内外处于3期临床试验阶段。 在2023年5月公布的OASIS 1研究中，试验基线平均 体重为 105.4 kg，在 667 名成年肥胖症或超重并伴有至少一种合并症的患者中， 口服司美格鲁肽50mg组患者68周体重平均减轻 17.4%（18.34kg） 。 在最新的OASIS 4研究公布了25mg口服司美格鲁肽的减重III期研究结果。这项研究为期64周，入组307名患者，基线体重105.9千克。结果显 示，口服司美格鲁肽组的体重平均下降了13.6%（14.4kg）。 若所有受试者完成治疗，口服司美格鲁肽组的减重幅度可达到 16.6%（17.6kg）。 此外，司美格鲁肽在整个研究过程中显示了良好的安全性和耐受性。 从现有数据来看，要达到与注射版相似的减重效果，口服版司美格鲁肽的剂量可能需要高达每日25mg甚至50mg，而目前市场上口服版司美格 鲁肽的最高剂量仅为14mg。此外， 不建议超 ...

Core Viewpoint - The article emphasizes the importance of integrating health weight management actions into the "Healthy China 2030" strategy to address the rising obesity rates and related health issues in the country [5][6]. Group 1: New Actions and Their Importance - The National Health Commission has added three new initiatives: Health Weight Management Action, Healthy Village Construction Action, and Traditional Chinese Medicine Health Promotion Action to the existing health strategies [3][4]. - The obesity issue in China is significant, with 34.3% of adults being overweight and 16.4% classified as obese, necessitating these new actions to prevent a rise in chronic diseases [5][6]. Group 2: Weight Management Strategies - Individuals and families are encouraged to monitor their health by regularly measuring weight and waist circumference, adopting a healthy diet based on the "three reductions" principle (reducing oil, salt, and sugar), and ensuring regular physical activity [7][10]. - Social support is crucial, with medical institutions establishing weight management clinics, schools limiting unhealthy snacks, and communities providing fitness facilities and healthy dining options [8][10]. - Government measures include promoting health education through media, monitoring national weight changes, and adjusting policies to ensure effective implementation [9][10]. Group 3: Business Opportunities and Innovations - The "Three Reductions and Three Health" policy is driving demand for low-sugar, high-protein meal replacements and low glycemic index foods, benefiting leading brands as regulatory scrutiny increases [11]. - Innovations in the industry include integrating smart health devices with meal replacement products for personalized nutrition tracking and developing foods that align with traditional Chinese medicine principles [12][13]. - The market for children's healthy snacks and innovative meal replacements is expanding, with established brands collaborating with medical institutions to enhance consumer trust and provide tailored health solutions [14].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 前不久的两会上提出了"全民减肥"的倡议，随后官方发布公告，宣布2025年为"体重管理年"。这绝非小题大做，国家亲自推动体重管理，其背 后究竟有何深层原因？今天就和大家一起探讨，这场"健康大棋"背后的深远意义。 ▍当肥胖成为"资本陷阱" 去过美国的人可能都发现，超市里总是摆满了高糖高油的廉价食品，麦当劳等快餐店更是经常能看到身材肥胖的顾客。 ▍个人破局之道 作为一名运动营养师，我亲眼见证了许多学员的蜕变之路。究竟怎样科学减肥？请牢记"三维管理法"——饮食创新、运动规划、睡眠优化。 1. 饮食方面： 早餐建议优选高质量蛋白配合复合碳水； 午餐遵循"442法则"（4份蔬菜+4份蛋白+2份粗粮）； 晚餐以低碳水高蛋白为主。 另 外，每天要确保摄入2升水，有助于提升身体代谢。 2. 运动方面： 每日至少运动30分钟。 燃脂训练组合：开合跳和高抬腿间隔交替，确保心率维持在120-140。 塑形训练重点：壶铃训练针对臀 部、腿部和核心，哑铃主要锻炼胸部、肩部和背部， ...